Headaches are a common symptom of a stressful lifestyle, your body not feeling well and other issues. While headaches can be dealt with easily, migraines are not so easy to handle. Migraines are a type of headache that feels like severe throbbing and pulsing sensation, almost like you are hearing your own heartbeat in your brain, usually on one side of the brain. Many people believe that migraines are not that big of a deal because you just have to deal with the pain, but that is not all migraine is, some people find it very difficult to do their daily tasks as they experience dizzying spells, nausea and extreme sensitivity to light and sound! These attacks can last hours and make it difficult for people to go about their daily lives as well. While there are medications available for migraine patients, these medications need time to take effect, so you may be in a lot of pain, but there are not many quick reliefs you can have in place other than learning the symptoms of a migraine attack and taking medication before it happens. But a new approval by the FDA may change this!

The U.S. Food and Drug Administration (FDA) has approved Symbravo, a new medicine to treat acute migraine attacks in adults. This means adults can now use Symbravo to get relief from their migraine symptoms. The FDA's decision was based on the results of three big studies, called Phase 3 trials. These trials involved over 21,000 migraine attacks, so the FDA has a lot of information about how well Symbravo works and how safe it is. The FDA only approves medicines that have been shown to be both safe and effective through a thorough testing process.

Importance of New Treatment Option

"Migraine attacks can happen suddenly and really mess up people's lives. It's estimated that over 39 million people in the U.S. alone get migraines," said Herriot Tabuteau, M.D., CEO of Axsome Therapeutics told US News. This shows how common migraines are and how important it is to have good treatments. "Symbravo gives patients and doctors a new option that can quickly stop a migraine attack, keep it away, and let people get back to their normal activities, all with just one dose." Having a medicine that can give fast and long-lasting relief from migraine pain is a big deal for millions of people. This new treatment is a real step forward in how we treat migraines.

Symbravo Trial Results, How Was It Approved

The trials took place in 3 steps, the Momentum trial study focused on people whose migraines had moderate to severe pain. The results showed that a lot more people taking Symbravo felt pain-free two hours after taking the medicine compared to those who took a placebo which is a dummy pill. Even better, many people felt relief for up to 24 and even 48 hours after just one dose. This long-lasting relief is really important for people with migraines because it means they can get back to their normal lives without worrying about the pain coming back. The study also looked at how many people were free from their worst symptom, like sensitivity to light or sound, or nausea. Symbravo worked better than the placebo in this area too.

While the intercept trial looked at people who took Symbravo when their migraine pain was still mild. Even when the pain was just starting, Symbravo was effective. The results were similar to the MOMENTUM trial, with many people getting pain relief and relief from their worst symptoms. Treating migraines early is often better because it can stop the pain from getting really bad.

And lastly the Movement trial which was to see how safe the medication is when people take it regularly. This study followed 706 people who had at least two migraines a month. The most common side effects people experienced were sleepiness and dizziness. While these side effects are important to know about, the study showed that Symbravo is generally safe for people to use on a regular basis.

Flu cases are starting to fall, yet experts caution that the United States still faces risks. In the week ending January 10, fifteen more children died from the flu, bringing the total pediatric deaths this season to 32, as per NBC News.

Flu Season: Latest CDC Data

On Friday, the Centers for Disease Control and Prevention (CDC) reported an 18% drop in confirmed flu cases compared with the previous week. Visits to doctors for respiratory illnesses decreased by more than 5%, and hospitalization rates fell by nearly 55%. Influenza-related deaths, however, rose by 2%.

So far this flu season, the CDC estimates that 18 million people have been infected, including 230,000 hospitalizations and 9,300 deaths.

“It seems like there is some cautious good news that cases are declining,” said Jennifer Nuzzo, director of the Pandemic Center at Brown University School of Public Health. “But I’m going to put a giant asterisk on this because that does not mean the worst is behind us.”

Last year, flu cases dipped around this time before climbing again in early February.

Flu Season: State-by-State Variation

CDC data reflect a national trend, but not all states have necessarily reached their peak. “We are not going to all experience this at the same time,” said Beth Carlton, a public health professor at the University of Colorado, as per NBC News. “Nationwide, the trend is downward, but different states and communities may see spikes as the virus spreads.”

Flu often appears first in densely populated areas like New York City before moving to rural regions, but the virus can behave unpredictably.

Flu Season: Impact on Schools

Although flu cases may be falling overall, other winter illnesses such as norovirus, Covid, and strep throat are still causing school closures in states including Arkansas, Kansas, Kentucky, Tennessee, and West Virginia.

High flu activity continues in Idaho, New Mexico, New York, and parts of Appalachia, while Montana, South Dakota, Vermont, and Wyoming report lower case numbers.

“The number of people hospitalized for influenza around New Year’s was extremely high—the second highest in the past decade, with last year being the highest,” Carlton said.

Flu Season: A Difficult Flu Season

This year’s severe flu season is driven by a heavily mutated strain of influenza A called H3N2 subclade K. Its mutations make it less similar to the strain used in this year’s vaccine. Influenza-like illnesses, including RSV and Covid, are also unusually high, Nuzzo said.

“Typically these viruses peak at different times, but this year they are peaking together, making the season particularly harsh,” she noted.

While there were concerns that the vaccine would be less effective against subclade K, recent research shows the current flu shot still offers protection, particularly against hospitalization. The vaccine covers three strains: H1N1, H3N2, and one B strain.

Flu Season: Pediatric Risk

As per NBC News, last year marked the deadliest flu season for children since the CDC began tracking pediatric deaths, with 289 children dying—more than during the 2009 H1N1 pandemic.

“That double peak last season clearly had consequences,” Nuzzo said. “Any decline this season is welcome, but we can’t assume the worst is over.”

Among children eligible for the flu shot whose vaccination status was known, 90% of pediatric deaths occurred in unvaccinated kids.

Following recent CDC guidance, flu shots are no longer recommended for all children, a change from the previous advice that everyone six months and older should be vaccinated annually.

The Saudi Arabian Food and Drug Authority has cleared Anktiva, an IL-15–based immunotherapy created by billionaire physician-scientist Patrick Soon-Shiong and his biotech firm ImmunityBio, for the treatment of bladder cancer and lung cancer. This marks the first time the therapy has received national regulatory approval outside the United States.

The move signals an important global step for Anktiva, which currently holds a limited approval from the U.S. Food and Drug Administration. In the U.S., the drug is authorised only for patients with BCG-unresponsive, non–muscle-invasive bladder cancer (NMIBC) that includes carcinoma in situ. American regulators have so far resisted expanding its use to other bladder cancer subtypes. Saudi regulators, however, have adopted a broader stance, approving Anktiva for two cancer types under their domestic regulatory system.

What Is Anktiva?

Anktiva is an interleukin-15 receptor agonist designed to stimulate the body’s own immune defences. It works by activating and expanding natural killer (NK) cells and memory CD8⁺ T cells, which play a key role in immune surveillance. Unlike chemotherapy or gene-based treatments, Anktiva does not attack tumour cells directly. Instead, it boosts existing immune pathways to help the body recognise and destroy cancer cells.

ImmunityBio describes Anktiva as “the first FDA-approved immunotherapy that activates what’s called a natural killer cell to target and kill non-muscle-invasive bladder cancer cells.” In clinical practice, the drug is used alongside BCG (Bacillus Calmette-Guérin) in patients whose NMIBC has not responded to BCG alone. It is administered directly into the bladder through a catheter, followed by a structured maintenance schedule

Clinical Evidence Supporting FDA Approval in NMIBC

The FDA’s approval, issued on April 22, 2024, was based on results from a single-arm clinical study involving 77 patients with BCG-unresponsive stage 0 NMIBC. Participants received intravesical Anktiva combined with BCG, with maintenance therapy continuing for as long as 37 months.

The main efficacy results were as follows:

• Complete response rate: 62%

Durability:

• 58% of patients who responded remained disease-free for at least 12 months
• 40% stayed disease-free for 24 months or longer

For patients facing the prospect of radical cystectomy as the only curative option, these results were considered clinically significant. Still, the absence of a randomised control group has remained a point of contention among regulators and experts.

Regulatory Tension in the United States

Although the FDA approved Anktiva for NMIBC cases involving carcinoma in situ, it declined to extend the indication to patients with papillary-only disease. ImmunityBio pushed back against the decision, arguing that the same clinical data had already been deemed sufficient to support approval in a closely related patient group.

Rachel Sherman, MD, former principal deputy commissioner of the FDA, publicly criticised the agency’s stance, saying: “it is incomprehensible to me that the FDA refuses to file a supplemental BLA, stating the study is not sufficient to support a regulatory review, when it has already approved a product based on that very same study in essentially the same indication and population.”

The FDA has also expressed concerns about how the drug has been marketed. It issued a warning letter to ImmunityBio over promotional materials that cited survival benefits and cystectomy-avoidance rates not supported by robust evidence.

Saudi regulators, by contrast, have taken a more permissive view, approving Anktiva for both bladder and lung cancer and highlighting a willingness to act in areas of high unmet medical need.

With this decision, Saudi Arabia becomes the first country to approve Anktiva beyond NMIBC, potentially placing itself at the forefront of evaluating the therapy’s wider role across multiple cancer types.

Once a rare condition, non-alcoholic fatty liver disease (NAFLD) now affects one in three Indians, scientists say.

NAFLD, now called as metabolic dysfunction-associated steatotic liver disease (MASLD), is when excess fat builds up in the liver, unrelated to heavy alcohol use, due to obesity, Type 2 diabetes, high blood pressure and cholesterol.

It ranges from simple fat accumulation to inflammation and damage, which can progress to fibrosis, cirrhosis or liver cancer, The disease often has no symptoms and is managed with lifestyle changes such as diet and weight loss.

A JAMA study has now found that about 40 percent of the global population is now suffering from NAFLD, with abdominal obesity identified as its single biggest risk factor. Between 2010 and 2021, India recorded a 13.2 percent increase in age-standardized prevalence, ranking just behind China at 16.9 percent and Sudan at 13.3 percent.

What Did The Study Find?

Researchers found that nearly 70 percent of people with Type 2 diabetes and about 80 percent of those with obesity are affected by NAFLD. They also discovered that NAFLD prevalence is higher in men than in women, with rates of 15,731 per 100,000 population in men compared with 14,310 in women.

Additionally, the disease peaks earlier in men, between 45 and 49 years of age, while women show the highest prevalence between 50 and 54 years.

Why Is NAFLD on the rise?

Experts also note that working long hours at desks without any proper physical activity can lead to weight gain and fat accumulation in the liver.

According to the Union health ministry, the prevalence of the condition could be in the range of 9-53 percent. Multiple other health studies also suggest nearly 40 percent of urban Indians may have some form of fatty liver disease

Hepatologist Dr Cyriac Abby Philips, popularly known as LiverDoc on social media, noted on X that many patients do not realize that timely lifestyle changes can completely reverse the condition. “All it takes is being in charge of your body and health. No shortcuts—go slow and steady,” he wrote.

If left untreated, NAFLD can progress to Non-Alcoholic Steatohepatitis (NASH), where liver inflammation begins. Over time, this inflammation can lead to scarring of the liver, known as fibrosis. Advanced fibrosis results in cirrhosis, which severely affects liver function.

NAFLD can also increase the risk of chronic liver disease, liver failure and hepatocellular carcinoma. Many patients diagnosed with liver cancer have a history of untreated fatty liver.